Amendments to the Claims

1-2. (Cancelled)

3. (Currently amended) The method of claim 6 ~~1~~, wherein each of said one or more antisense oligomers has a length of about 12 to 25 bases.

4. (Cancelled)

5. (Currently amended) The method of claim 6 ~~1~~, wherein said antisense morpholino oligomer comprises phosphorodiamidate intersubunit linkages, joining a morpholino nitrogen of one morpholino subunit to a 5'-exocyclic carbon of an adjacent morpholino subunit.

6. (Currently amended) ~~The method according to claim 1, wherein each of said one or more antisense oligomers has~~ A method of promoting hematopoietic stem cell differentiation, comprising:

contacting hematopoietic stem cells *in vitro* with one or more antisense morpholino oligomers having a substantially uncharged backbone and the sequence presented as SEQ ID NO:1.

7-9. (Cancelled)

10. (Currently amended) The method of claim 6 ~~1~~, wherein said hematopoietic stem cells are provided by:

(a) obtaining a stem cell-containing cell population from a subject; and

(b) treating the cell population in manner effective to enrich the cell population for stem cells.

11-18. (Cancelled)

19. (Previously presented) A composition comprising an antisense oligomer having an uncharged backbone, wherein said antisense oligomer is characterized by

(a) the ability to hybridize with the complementary sequence of a target RNA with high affinity at a Tm greater than 50°C,

(b) nuclease resistance, and

(c) the capability for active or facilitated transport into cells;

and has the sequence presented as SEQ ID NO:1.

20. (Cancelled)

21. (Previously presented) The method of claim 10, further comprising the step of infusing the antisense oligomer-treated cell population into said subject.

22. (Currently amended) An antisense morpholino oligomer characterized by a backbone which is substantially uncharged ~~The composition of claim 17~~, wherein said oligomer has the base sequence presented as SEQ ID NO:1.